Postoperative atrial fibrillation prevention after open-heart surgery
Amiodarone is commonly initiated after open-heart surgery to prevent new-onset postoperative atrial fibrillation (POAF) in patients at high risk. POAF prevention reduces arrhythmia burden and associated postoperative complications such as hemodynamic instability and neurologic events. [1][2]
Medication Selection Algorithm
Short-term perioperative antiarrhythmic prophylaxis is typically used in high-risk cardiac surgery patients. [1]
- Perioperative oral amiodarone (used as short-term prophylaxis) [1]
- Alternative prophylactic strategy in similar patients: short-term prophylactic beta blockers (used when amiodarone is not used or is contraindicated) [1]
Key Evidence Supporting This Recommendation
A 2025/2026 meta-analysis of randomized trials in cardiac surgery patients found perioperative amiodarone reduced POAF incidence (odds ratio 0.39, 95% CI 0.31–0.49). [3]
The benefit of perioperative amiodarone has been reproduced across multiple perioperative strategies, with meta-analytic signals favoring the impact of timing and route over cumulative dose alone. [3]
Monotherapy vs Combination Therapy
Amiodarone is used as prophylaxis in combination with other standard perioperative AF prevention measures such as beta blockers in many care pathways. [1][3]
Evidence synthesis supports that prophylactic regimens can reduce POAF but also shows bradycardia risk signals with amiodarone. [3]
Important Clarifications and Nuances
Amiodarone prophylaxis is supported specifically for cardiac surgery POAF prevention rather than as routine long-term therapy. [1]
Safety tradeoffs include increased bradycardia risk observed in randomized evidence synthesis, which supports selection and monitoring rather than indiscriminate use. [3]
Initiation Thresholds or Indications
High-risk cardiac surgery patients are the target population for short-term prophylactic amiodarone. [1]
The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline states that short-term prophylactic beta blockers or amiodarone is reasonable in patients undergoing cardiac surgery who are at high risk for postoperative AF. (Class 2a recommendation) [1]
The 2026 Society of Thoracic Surgeons guideline includes class-based recommendations for perioperative oral amiodarone for prevention of new-onset POAF after cardiac surgery. [2]
Common Pitfalls to Avoid
Routine long-term antiarrhythmic treatment after surgery should be avoided because guideline support is for short-term perioperative prophylaxis. [1][2]
Bradycardia risk should be anticipated because perioperative amiodarone increased bradycardia risk in meta-analysis of randomized trials. [3]
Treatment Goals
The clinical goal of perioperative amiodarone initiation is reduction in the incidence of new-onset POAF after cardiac surgery. [1][3]
Secondary goals include reducing consequences of POAF through decreased arrhythmia occurrence in the postoperative period. [2][3]